Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ3510LO2W
Performance in the last:
Follow this Portfolio
1D 3.2 %
1W 5.0 %
2W 0.2 %
1M -1.1 %
3M 5.0 %
6M 1.2 %
9M 3.6 %
1Y -5.6 %
Alpha
-18.1%
Beta
0.63
sharpe-R
-0.05
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
2.12
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2024-09-16 06:53:37
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -18.3%
Max. DrawDown Benchmark -8.41%

This Long Only strategy aims to find promising assets to invest in for a maximum holding period of 2 Weeks in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 10.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
3
Difficulty Level
2

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

Asset Asset Class Action Weight PnL
TVTX Travere Therapeutics, Inc. Equity Buy 12.71% 40.42%
ESPR Esperion Therapeutics, Inc. Equity Buy 9.45% 4.37%
NVCR NovoCure Limited Equity Buy 9.39% 2.88%
MYGN Myriad Genetics, Inc. Equity Buy 9.34% 2.3%
The percentage of cash held in the portfolio is: 59.11%
** The description of each asset is available Here

The latest 5 Compositions change

2024-09-12 00:00:00 : Portfolio change date
Asset Action Weight PnL
TVTX Travere Therapeutics, Inc. Buy 11.92% 27.5%
ESPR Esperion Therapeutics, Inc. Buy 8.89% -4.92%
NVCR NovoCure Limited Buy 9% -4.54%
MYGN Myriad Genetics, Inc. Buy 9.18% -2.56%
The percentage of cash held in the portfolio is: 61.02%
New Assets Added
None
Assets Removed
Asset Action Perf %
PODD Sell All 11.4%
Assets Rebalanced
None
2024-09-10 00:00:00 : Portfolio change date
Asset Action Weight PnL
PODD Insulet Corporation Buy 10.99% 7.2%
TVTX Travere Therapeutics, Inc. Buy 12.53% 33.96%
ESPR Esperion Therapeutics, Inc. Buy 8.69% -7.1%
NVCR NovoCure Limited Buy 8.68% -7.98%
MYGN Myriad Genetics, Inc. Buy 9.49% 0.63%
The percentage of cash held in the portfolio is: 49.62%
New Assets Added
None
Assets Removed
Asset Action Perf %
ALDX Sell All -6.49%
AADI Sell All 3.43%
Assets Rebalanced
None
2024-09-09 00:00:00 : Portfolio change date
Asset Action Weight PnL
AADI Aadi Bioscience, Inc. Buy 10.88% 4.57%
PODD Insulet Corporation Buy 10.97% 5.05%
TVTX Travere Therapeutics, Inc. Buy 10.89% 14.37%
ESPR Esperion Therapeutics, Inc. Buy 8.58% -9.84%
ALDX Aldeyra Therapeutics, Inc. Buy 9.29% -3.01%
NVCR NovoCure Limited Buy 8.98% -6.48%
MYGN Myriad Genetics, Inc. Buy 9.6% 0%
The percentage of cash held in the portfolio is: 30.81%
New Assets Added
  • MYGN
Assets Removed
None
Assets Rebalanced
None
2024-09-06 00:00:00 : Portfolio change date
Asset Action Weight PnL
AADI Aadi Bioscience, Inc. Buy 10.69% 2.86%
PODD Insulet Corporation Buy 11.03% 5.72%
TVTX Travere Therapeutics, Inc. Buy 9.84% 3.44%
ESPR Esperion Therapeutics, Inc. Buy 8.94% -6.01%
ALDX Aldeyra Therapeutics, Inc. Buy 9.56% 0%
NVCR NovoCure Limited Buy 9.59% 0%
The percentage of cash held in the portfolio is: 40.36%
New Assets Added
  • NVCR
Assets Removed
Asset Action Perf %
CARA Sell All -6.41%
AGEN Sell All -8.59%
Assets Rebalanced
None
2024-09-05 00:00:00 : Portfolio change date
Asset Action Weight PnL
CARA Cara Therapeutics, Inc. Buy 9.75% -6.12%
AGEN Agenus Inc. Buy 9.21% -11.33%
AADI Aadi Bioscience, Inc. Buy 10.67% 2.86%
PODD Insulet Corporation Buy 10.82% 3.96%
TVTX Travere Therapeutics, Inc. Buy 9.93% 4.69%
ESPR Esperion Therapeutics, Inc. Buy 9.44% -0.55%
ALDX Aldeyra Therapeutics, Inc. Buy 9.54% 0%
The percentage of cash held in the portfolio is: 30.63%
New Assets Added
  • ALDX
Assets Removed
Asset Action Perf %
CERS Sell All -11.34%
APLS Sell All -5.21%
ORGO Sell All -4.59%
EGRX Sell All -11.35%
Assets Rebalanced
None
2024-09-04 00:00:00 : Portfolio change date
Asset Action Weight PnL
APLS Apellis Pharmaceuticals, Inc. Buy 10.08% -2.65%
ORGO Organogenesis Holdings Inc. Buy 9.99% -3.53%
CARA Cara Therapeutics, Inc. Buy 10% -3.5%
AGEN Agenus Inc. Buy 9.38% -9.51%
CERS Cerus Corporation Buy 9.52% -7.98%
AADI Aadi Bioscience, Inc. Buy 10.29% -0.57%
PODD Insulet Corporation Buy 10.5% 1.11%
EGRX Eagle Pharmaceuticals, Inc. Buy 9.3% -10.38%
TVTX Travere Therapeutics, Inc. Buy 9.47% 0%
ESPR Esperion Therapeutics, Inc. Buy 9.47% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • TVTX
  • ESPR
Assets Removed
Asset Action Perf %
ARDX Sell All -11.62%
NEOG Sell All -6.34%
Assets Rebalanced
None

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings